Is Tesamorelin Acetate the Same as Tesamorelin? (Clarified)

If you've seen 'tesamorelin' and 'tesamorelin acetate' used interchangeably in research peptide catalogs, clinical trial reports, or FDA documentation. You're not imagining things. The naming isn't careless: tesamorelin acetate is the acetate salt form of tesamorelin, and it's the only form you'll encounter in practical use. The base peptide (tesamorelin) is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH), but without the acetate counterion stabilizing the molecule, it degrades rapidly in solution and can't be reconstituted reliably. Every clinical formulation, every research-grade vial, every FDA-approved preparation. They all use tesamorelin acetate, not 'free base' tesamorelin.

Our team has worked with peptide researchers and compounding facilities for years. The distinction between these two names matters only in one context: understanding why the molecular weight listed on your certificate of analysis (CoA) differs slightly from literature values for 'tesamorelin' alone.

Is tesamorelin acetate the same as tesamorelin?

Yes. Tesamorelin acetate and tesamorelin refer to the same peptide in all practical research and clinical contexts. The 'acetate' designation specifies that the peptide is supplied as an acetate salt, the stabilized form required for lyophilization, storage, and reconstitution. When dissolved in bacteriostatic water, the acetate counterion dissociates, leaving active tesamorelin to bind GHRH receptors in the anterior pituitary. The molecular weight difference between tesamorelin (5135.89 Da) and tesamorelin acetate accounts for the acetate groups. But both names describe the identical 44-amino-acid GHRH analog used in research.

What the Acetate Designation Means for Stability and Handling

The acetate salt form exists because peptides like tesamorelin are inherently unstable in aqueous solution. The amide bonds linking amino acids are vulnerable to hydrolysis, oxidation, and aggregation. Lyophilizing the peptide as an acetate salt removes water, locks the molecule into a stable crystalline or amorphous solid, and protects it from degradation during storage at −20°C. When you reconstitute tesamorelin acetate with bacteriostatic water, the acetate groups dissociate immediately. What remains is bioactive tesamorelin capable of stimulating growth hormone (GH) release via GHRH receptor activation.

The practical implication: whether your supplier labels the product 'tesamorelin' or 'tesamorelin acetate,' you're receiving the same compound. The acetate counterion is a delivery mechanism, not a structural modification. This differs meaningfully from peptides like semaglutide, where the base peptide and the acetate salt are pharmacologically distinct formulations with different absorption kinetics. Tesamorelin acetate and tesamorelin are identical in action once reconstituted.

Certificate of analysis (CoA) documentation typically lists molecular weight as 5135.89 Da for tesamorelin or slightly higher (approximately 5255 Da) when acetate groups are included in the calculation. This variance doesn't indicate impurity. It reflects whether the supplier is reporting the peptide alone or the acetate salt complex. Both are correct; the difference is nomenclature convention.

How Tesamorelin Works as a GHRH Analog

Tesamorelin is a synthetic 44-amino-acid sequence that mimics the structure of endogenous human growth hormone-releasing hormone (GHRH-1-44), with a trans-3-hexenoic acid modification at the N-terminus that extends the peptide's half-life from under 10 minutes to approximately 26–38 minutes in circulation. This modification prevents rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), the enzyme responsible for cleaving naturally occurring GHRH within seconds of secretion.

Once administered subcutaneously, tesamorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary gland, triggering cyclic AMP (cAMP) signaling that stimulates growth hormone synthesis and pulsatile GH release. Unlike exogenous recombinant human growth hormone (rhGH), which delivers GH directly and suppresses endogenous production through negative feedback, tesamorelin preserves the body's natural GH secretion pattern. Meaning pituitary function remains intact and physiological pulsatility is maintained.

Clinical trials in HIV-associated lipodystrophy demonstrated that 2 mg daily subcutaneous tesamorelin reduced visceral adipose tissue (VAT) by 15–18% over 26 weeks, with corresponding reductions in trunk fat and improvements in insulin sensitivity markers. The mechanism is indirect: elevated GH levels stimulate lipolysis (fat breakdown) via hormone-sensitive lipase (HSL) activation, increase fatty acid oxidation in the liver, and enhance lean body mass retention through anabolic signaling in skeletal muscle. This pathway is why tesamorelin shows specificity for visceral fat reduction. VAT is more metabolically active and more responsive to GH-mediated lipolysis than subcutaneous fat.

Why Molecular Weight Matters When Comparing Supplier Data

If you're cross-referencing certificates of analysis from multiple peptide suppliers, you'll notice molecular weight discrepancies: one supplier lists 5135.89 Da, another lists 5255 Da, and a third might report 5136 Da rounded. These aren't errors or indicators of product variance. They reflect different reporting conventions for the acetate counterion.

The 5135.89 Da figure represents tesamorelin as the free peptide (44 amino acids with the trans-3-hexenoic acid modification). The 5255 Da figure includes the molecular weight contribution of acetate groups used to stabilize the peptide during lyophilization. Typically two acetate ions per molecule, adding approximately 118 Da total. Both are correct depending on whether the supplier is listing the peptide backbone alone or the entire salt complex as shipped.

This distinction becomes relevant when calculating reconstitution concentrations or verifying purity via HPLC (high-performance liquid chromatography). If you're dosing based on 'mg of peptide,' you need to know whether the labeled mass includes acetate. Most research peptide suppliers use 'peptide content' (net peptide weight excluding counterions) on their CoAs, but not all. A 5 mg vial labeled 'tesamorelin acetate' at 98% purity might contain 4.9 mg of active tesamorelin once acetate mass is excluded. The acetate groups dissociate upon reconstitution and are not pharmacologically active.

At Real Peptides, every CoA specifies whether molecular weight includes counterions. This transparency prevents dosing errors and ensures reproducibility across research protocols. If your supplier doesn't clarify this, ask before reconstituting.

Tesamorelin Acetate Same as Tesamorelin: Practical Implications for Reconstitution

Because tesamorelin acetate and tesamorelin are functionally identical, reconstitution protocols don't change based on nomenclature. Standard practice is to dissolve lyophilized tesamorelin acetate in bacteriostatic water (0.9% benzyl alcohol) at a concentration of 2 mg/mL for research use. This matches the dosing used in clinical trials and minimizes injection volume.

Reconstitution steps: (1) Allow the vial to reach room temperature for 10–15 minutes to prevent condensation. (2) Add bacteriostatic water slowly down the inside wall of the vial. Never inject directly onto the lyophilized powder, as mechanical stress can fragment the peptide. (3) Swirl gently. Do not shake. Agitation introduces air bubbles that denature peptides at the air-water interface. (4) Refrigerate immediately at 2–8°C once fully dissolved. Reconstituted tesamorelin acetate is stable for 14–21 days under refrigeration; beyond that window, peptide aggregation and oxidation degrade potency measurably.

Our experience with research clients shows that the most common reconstitution error isn't contamination or incorrect concentration. It's injecting air into the vial during solution withdrawal. The pressure differential created by withdrawing liquid without replacing air volume pulls contaminants backward through the needle on subsequent draws. Use a second sterile needle to vent air during withdrawal, or use proper aseptic technique with a syringe system that equalizes pressure.

Tesamorelin Acetate Same as Tesamorelin: Supplier Comparison

What If: Tesamorelin Storage and Handling Scenarios

What If I Received a Vial Labeled 'Tesamorelin' Without the Acetate Designation?

Proceed with standard reconstitution. The product is almost certainly tesamorelin acetate regardless of labeling. Free-base tesamorelin (without a stabilizing counterion) is not viable for commercial distribution because it degrades within hours at room temperature. Contact your supplier to confirm the molecular weight listed on the CoA matches 5255 Da or 5136 Da (both acceptable). If the supplier cannot provide a CoA with molecular weight and purity verification, do not use the product. Absence of documentation indicates inadequate quality control.

What If the CoA Lists a Purity Below 95%?

Peptides below 95% purity contain significant impurities. Truncated sequences, aggregated dimers, or synthesis byproducts that interfere with GHRH receptor binding. Research-grade tesamorelin acetate should consistently test ≥98% purity via HPLC. If your supplier's batch tests below 95%, request a replacement or source from a verified 503B-registered facility. Impure peptides not only reduce efficacy but also increase the risk of immune reactions due to contaminated sequences the body recognizes as foreign.

What If I Accidentally Froze Reconstituted Tesamorelin Acetate?

Discard the vial. Freezing reconstituted peptides causes ice crystal formation that ruptures peptide structures and denatures the molecule irreversibly. Once thawed, the solution may appear clear, but HPLC analysis would show fragmented peptides and aggregated dimers that no longer bind GHRH receptors effectively. Lyophilized (unreconstituted) tesamorelin acetate tolerates freezing at −20°C indefinitely, but once dissolved, it must remain refrigerated at 2–8°C without temperature excursions.

The Evidence-Based Truth About Tesamorelin Nomenclature

Here's the honest answer: the naming distinction between tesamorelin acetate and tesamorelin is entirely pharmaceutical convention. Not a pharmacological difference. Every tesamorelin product you'll encounter in clinical, compounding, or research contexts is the acetate salt form. The 'acetate' label isn't hiding anything; it's specifying the stabilization method used during manufacturing.

The confusion arises because FDA-approved formulations like Egrifta list 'tesamorelin (as acetate)' on patient labeling, while research suppliers often shorten it to 'tesamorelin' for brevity. Both are referring to the same molecule. The only time this matters is when calculating molar concentrations for receptor binding assays or verifying dosing accuracy from CoA data. And in those cases, the molecular weight listed on the CoA (whether 5136 Da or 5255 Da) tells you which convention the supplier used.

If a supplier tries to differentiate 'tesamorelin' from 'tesamorelin acetate' as separate products with different efficacy profiles, that's a red flag. The acetate counterion has zero pharmacological activity. It dissociates in solution and is excreted unchanged. What matters is peptide purity, sequence fidelity, and storage conditions. A 98%-pure tesamorelin acetate vial stored correctly at −20°C will outperform a 92%-pure 'tesamorelin' vial stored improperly every time.

How Real Peptides Ensures Tesamorelin Acetate Quality

Our synthesis process begins with solid-phase peptide synthesis (SPPS) using Fmoc chemistry to build the 44-amino-acid sequence with the trans-3-hexenoic acid modification at the N-terminus. Each batch undergoes third-party HPLC verification to confirm ≥98% purity, followed by mass spectrometry to validate the exact molecular weight and detect any truncated or misfolded sequences. The lyophilized tesamorelin acetate is packaged under sterile conditions in 2 mg or 5 mg vials with desiccant to prevent moisture exposure during shipping.

Every vial ships with a certificate of analysis (CoA) that lists peptide content (net tesamorelin excluding acetate mass), molecular weight (5255 Da for the acetate salt complex), purity percentage, and reconstitution recommendations. This level of documentation isn't standard across the peptide supply industry. Many vendors provide generic CoAs without batch-specific verification or omit molecular weight entirely. We've seen research protocols fail because dosing calculations assumed one molecular weight convention when the supplier used another.

If you're sourcing tesamorelin acetate for long-term research, verify that your supplier can provide batch-specific CoAs with HPLC chromatograms and mass spec data. Generic 'Certificate of Authenticity' documents without quantitative purity data are insufficient. You can explore our full peptide collection to see how transparency in testing and documentation supports reproducible research outcomes.

The distinction between tesamorelin acetate and tesamorelin isn't a formulation secret. It's a stabilization requirement. Once you understand that acetate is the counterion used to lyophilize and store the peptide, the nomenclature stops being confusing and becomes a quality signal. Suppliers who clarify molecular weight conventions and provide third-party purity verification are the ones producing research-grade peptides you can dose with confidence.

FAQs

[
{
"question": "Is tesamorelin acetate the same as tesamorelin in terms of biological activity?",
"answer": "Yes. Tesamorelin acetate and tesamorelin are biologically identical. The acetate designation refers to the salt form used to stabilize the peptide during lyophilization and storage. Once reconstituted in bacteriostatic water, the acetate counterion dissociates, leaving active tesamorelin that binds GHRH receptors and stimulates growth hormone release. The pharmacological mechanism, receptor affinity, and half-life (26–38 minutes) are unchanged."
},
{
"question": "Why do some suppliers list tesamorelin and others list tesamorelin acetate?",
"answer": "Both terms refer to the same compound. The difference is labeling convention. Research peptide suppliers often use 'tesamorelin acetate' to specify the stabilized salt form, while clinical formulations and some vendors shorten it to 'tesamorelin' for brevity. The molecule you receive is identical regardless of which name appears on the label. What matters is the certificate of analysis (CoA) confirming peptide purity (≥98%) and molecular weight."
},
{
"question": "Does the molecular weight difference between tesamorelin and tesamorelin acetate affect dosing?",
"answer": "It affects how you interpret the CoA, not the dose itself. Tesamorelin as the free peptide has a molecular weight of 5135.89 Da; tesamorelin acetate (including acetate groups) is approximately 5255 Da. If your supplier lists 5 mg of 'tesamorelin acetate,' that includes the acetate mass. The net peptide content (what's pharmacologically active) is slightly lower. Most research suppliers report 'peptide content' excluding counterions, but verify this with your supplier to avoid dosing errors."
},
{
"question": "Can I use tesamorelin acetate if the label just says tesamorelin?",
"answer": "Yes. The product is almost certainly tesamorelin acetate regardless of shortened labeling. Free-base tesamorelin without a stabilizing counterion degrades too rapidly to be distributed commercially. Verify the molecular weight on the CoA: if it's listed as 5255 Da or 5136 Da (both acceptable conventions), the product is suitable for research use. If no CoA is provided or molecular weight is omitted, source from a verified supplier instead."
},
{
"question": "How long does reconstituted tesamorelin acetate remain stable?",
"answer": "Reconstituted tesamorelin acetate remains stable for 14–21 days when stored at 2–8°C in bacteriostatic water. Beyond this window, peptide aggregation and oxidation reduce potency measurably. Lyophilized (unreconstituted) tesamorelin acetate is stable for years at −20°C, but once dissolved, it must be refrigerated continuously. Freezing reconstituted tesamorelin causes irreversible denaturation. If accidentally frozen, discard the vial."
},
{
"question": "What purity level should I expect from research-grade tesamorelin acetate?",
"answer": "Research-grade tesamorelin acetate should test ≥98% purity via HPLC, with mass spectrometry confirmation of the correct molecular weight. Purity below 95% indicates contamination with truncated sequences, aggregated dimers, or synthesis byproducts that interfere with GHRH receptor binding. If your supplier cannot provide third-party HPLC verification showing ≥98% purity, the peptide is not suitable for reproducible research."
},
{
"question": "Does tesamorelin acetate require special reconstitution compared to other peptides?",
"answer": "No. Tesamorelin acetate follows standard peptide reconstitution protocols. Add bacteriostatic water slowly down the vial wall (never directly onto the powder), swirl gently without shaking, and refrigerate at 2–8°C once dissolved. The acetate counterion dissociates immediately upon contact with water, so no additional steps are required. The most common error is injecting air into the vial during withdrawal, which pulls contaminants backward through the needle. Use proper aseptic technique or a venting needle."
},
{
"question": "Is tesamorelin acetate the same formulation used in FDA-approved Egrifta?",
"answer": "Yes. Egrifta contains tesamorelin as the acetate salt at 2 mg per dose. The molecular structure and pharmacological activity are identical to research-grade tesamorelin acetate, but Egrifta is supplied as a pre-measured lyophilized powder with a separate diluent vial for patient use. Research-grade tesamorelin acetate from 503B-registered suppliers uses the same active compound but without FDA approval for human therapeutic use."
},
{
"question": "Can tesamorelin acetate be used interchangeably with recombinant human growth hormone (rhGH)?",
"answer": "No. Tesamorelin acetate and rhGH work through different mechanisms. Tesamorelin stimulates the pituitary to release endogenous growth hormone in pulses, preserving natural GH secretion patterns and avoiding negative feedback suppression. rhGH delivers exogenous GH directly, which suppresses pituitary function over time. Tesamorelin is specific for visceral fat reduction via GH-mediated lipolysis; rhGH has broader anabolic effects but different safety and regulatory considerations."
},
{
"question": "What should I do if my tesamorelin acetate CoA lists a molecular weight I do not recognize?",
"answer": "Contact the supplier immediately to clarify whether the listed molecular weight includes acetate counterions. The two acceptable values are 5135.89 Da (peptide only) and approximately 5255 Da (acetate salt). If the CoA lists a significantly different value. Or provides no molecular weight at all. The product may be mislabeled, impure, or incorrectly synthesized. Do not reconstitute or use the peptide until you receive clarification and, if necessary, third-party verification."
}
]

References

Peer-reviewed sources on Tesamorelin indexed in PubMed, listed for research context. Real Peptides supplies Tesamorelin for laboratory research use only.

1. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity research & clinical practice, 2026. PMID 41545261. doi:10.1016/j.orcp.2026.01.002
2. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs, 2011. PMID 21668043. doi:10.2165/11202240-000000000-00000
3. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. The Journal of infectious diseases, 2025. PMID 39813152. doi:10.1093/infdis/jiaf012
4. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS (London, England), 2024. PMID 38905488. doi:10.1097/QAD.0000000000003965
5. Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. Journal of clinical and translational science, 2023. PMID 36845310. doi:10.1017/cts.2022.515
6. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS (London, England), 2021. PMID 33756511. doi:10.1097/QAD.0000000000002897
7. Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Scientific reports, 2021. PMID 34006921. doi:10.1038/s41598-021-89966-y
8. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI insight, 2020. PMID 32701508. doi:10.1172/jci.insight.140134